Will Earnings Beat Estimates? Ultragenyx Pharmaceutical Inc. (RARE) Stock
Wells Fargo raised the price target for the Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock to “an Overweight”. The rating was released on December 08, 2023, according to finviz. The research report from Evercore ISI has upgraded the stock from In-line to Outperform, with a price target set at $80. The stock was initiated by Cantor Fitzgerald, […]
Yummy or too sour? Ultragenyx Pharmaceutical Inc. (RARE) Stock
Wells Fargo raised the price target for the Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock to “an Overweight”. The rating was released on December 08, 2023, according to finviz. The research report from Evercore ISI has upgraded the stock from In-line to Outperform, with a price target set at $80. The stock was initiated by Cantor Fitzgerald, […]
Wells Fargo Assigned “an Overweight” Rating to Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock
Wells Fargo raised the price target for the Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock to “an Overweight”. The rating was released on December 08, 2023, according to finviz. The research report from Evercore ISI has upgraded the stock from In-line to Outperform, with a price target set at $80. The stock was initiated by Cantor Fitzgerald, […]
Will Earnings Beat Estimates? Ultragenyx Pharmaceutical Inc. (RARE) Stock
Wells Fargo raised the price target for the Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock to “an Overweight”. The rating was released on December 08, 2023, according to finviz. The research report from Evercore ISI has upgraded the stock from In-line to Outperform, with a price target set at $80. The stock was initiated by Cantor Fitzgerald, […]
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Price Advanced 0.88% to $47.00
Wells Fargo raised the price target for the Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock to “an Overweight”. The rating was released on December 08, 2023, according to finviz. The research report from Evercore ISI has upgraded the stock from In-line to Outperform, with a price target set at $80. The stock was initiated by Cantor Fitzgerald, […]
